Sophia Genetics SA
SOPH4.780USD
+0.170+3.69%
收盘 12/22, 16:00（美东）报价延迟15分钟
324.31M总市值
亏损市盈率 TTM
关于 Sophia Genetics SA 公司
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
Sophia Genetics SA简介
公司代码SOPH
公司名称Sophia Genetics SA
上市日期Jul 23, 2021
CEOCamblong (Jurgi)
员工数量423
证券类型Ordinary Share
年结日Jul 23
公司地址La Piece 12
城市ROLLE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Switzerland
邮编CH-1180
电话41216941060
网址https://www.sophiagenetics.com/
公司代码SOPH
上市日期Jul 23, 2021
CEOCamblong (Jurgi)
Sophia Genetics SA公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
2.65M
+7.89%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
443.81K
+12.21%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
396.61K
-4.26%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
234.25K
+25.98%
Mr. Didier Hirsch
Mr. Didier Hirsch
Non-Executive Independent Director
Non-Executive Independent Director
133.93K
+79.72%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
128.13K
+108.22%
Ms. Manuela Da Silva Valente
Ms. Manuela Da Silva Valente
Chief People Officer
Chief People Officer
60.38K
+51.32%
Dr. Philippe Menu, M.D., Ph.D.
Dr. Philippe Menu, M.D., Ph.D.
Chief Medical Officer and Chief Product Officer
Chief Medical Officer and Chief Product Officer
39.60K
-5.14%
Mr. George A. Cardoza
Mr. George A. Cardoza
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jean-Michel Cossiery, Ph.D.
Mr. Jean-Michel Cossiery, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
2.65M
+7.89%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
443.81K
+12.21%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
396.61K
-4.26%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
234.25K
+25.98%
Mr. Didier Hirsch
Mr. Didier Hirsch
Non-Executive Independent Director
Non-Executive Independent Director
133.93K
+79.72%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
128.13K
+108.22%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
Rest of EMEA
5.78M
31.53%
Italy
2.78M
15.19%
France
2.72M
14.82%
United States
2.66M
14.52%
Spain
1.63M
8.90%
其他
2.75M
15.04%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月4日 周二
更新时间: 11月4日 周二
持股股东
股东类型
持股股东
持股股东
占比
Alychlo NV
10.31%
Generation Investment Management LLP
10.01%
aMoon Fund
8.12%
Akre Capital Management, LLC
5.48%
Balderton Capital (UK) LLP
4.96%
其他
61.13%
持股股东
持股股东
占比
Alychlo NV
10.31%
Generation Investment Management LLP
10.01%
aMoon Fund
8.12%
Akre Capital Management, LLC
5.48%
Balderton Capital (UK) LLP
4.96%
其他
61.13%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
16.17%
Venture Capital
13.08%
Family Office
10.36%
Investment Advisor
8.43%
Individual Investor
6.43%
Hedge Fund
1.05%
Bank and Trust
0.46%
Research Firm
0.06%
Pension Fund
0.03%
其他
43.93%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
76
26.89M
39.64%
-8.96M
2025Q2
89
36.69M
54.29%
-200.15K
2025Q1
93
36.63M
54.82%
-389.48K
2024Q4
93
32.50M
49.36%
-965.83K
2024Q3
91
34.60M
52.08%
+657.87K
2024Q2
92
32.44M
48.93%
+1.33M
2024Q1
93
31.91M
48.51%
+375.11K
2023Q4
91
30.61M
46.76%
-676.23K
2023Q3
91
30.34M
46.61%
-4.34M
2023Q2
90
31.34M
48.19%
-3.70M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Alychlo NV
6.99M
10.35%
--
--
Feb 15, 2025
Generation Investment Management LLP
6.79M
10.05%
--
--
Jun 30, 2025
aMoon Fund
5.51M
8.15%
+577.36K
+11.70%
Feb 15, 2025
Akre Capital Management, LLC
3.72M
5.5%
+1.48M
+66.22%
Jun 30, 2025
Balderton Capital (UK) LLP
3.36M
4.97%
--
--
Feb 15, 2025
Camblong (Jurgi)
2.65M
3.93%
+194.16K
+7.89%
Feb 15, 2025
Banque Pictet & Cie S.A.
2.21M
3.27%
-2.76K
-0.12%
Jun 30, 2025
Principal Global Investors (Equity)
1.40M
2.07%
+15.15K
+1.09%
Jun 30, 2025
Ossipow (Vincent)
443.81K
0.66%
+48.31K
+12.21%
Feb 15, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Health Innovation Active ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
iShares Health Innovation Active ETF
占比0%
Fidelity Nasdaq Composite Index ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Sophia Genetics SA的前五大股东是谁？
Sophia Genetics SA 的前五大股东如下：
Alychlo NV持有股份：6.99M，占总股份比例：10.35%。
Generation Investment Management LLP持有股份：6.79M，占总股份比例：10.05%。
aMoon Fund持有股份：5.51M，占总股份比例：8.15%。
Akre Capital Management, LLC持有股份：3.72M，占总股份比例：5.50%。
Balderton Capital (UK) LLP持有股份：3.36M，占总股份比例：4.97%。
Alychlo NV持有股份：6.99M，占总股份比例：10.35%。
Generation Investment Management LLP持有股份：6.79M，占总股份比例：10.05%。
aMoon Fund持有股份：5.51M，占总股份比例：8.15%。
Akre Capital Management, LLC持有股份：3.72M，占总股份比例：5.50%。
Balderton Capital (UK) LLP持有股份：3.36M，占总股份比例：4.97%。
Sophia Genetics SA的前三大股东类型是什么？
Sophia Genetics SA 的前三大股东类型分别是：
Alychlo NV
Generation Investment Management LLP
aMoon Fund
Alychlo NV
Generation Investment Management LLP
aMoon Fund
有多少机构持有Sophia Genetics SA(SOPH)的股份？
截至2025Q3，共有76家机构持有Sophia Genetics SA的股份，合计持有的股份价值约为26.89M，占公司总股份的39.64%。与2025Q2相比，机构持股有所增加，增幅为-14.66%。
哪个业务部门对Sophia Genetics SA的收入贡献最大？
在FY2025Q2，--业务部门对Sophia Genetics SA的收入贡献最大，创收--，占总收入的--%。
